We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Hospira UK Ltd

Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, UK
Fax: +44 (0)800 098 8653
Medical Information Direct Line: 1 800 633 363

Summary of Product Characteristics last updated on medicines.ie: 08/08/2017
SPC Cisplatin

Go to top of the page

Cisplatin 1 mg/ml Concentrate for Solution for Infusion

Go to top of the page

1 ml of concentrate for solution for infusion contains 1 mg of cisplatin.

1 vial of 10 ml concentrate for solution for infusion contains 10 mg of cisplatin. 1 vial of 50 ml concentrate for solution for infusion contains 50 mg of cisplatin. 1 vial of 100 ml concentrate for solution for infusion contains 100 mg of cisplatin.

Also contains sodium 9 mg/ml

For a full list of excipients, see 6.1.

Go to top of the page

Concentrate for Solution for Infusion.

Clear, colourless to pale yellow solution

Go to top of the page

Go to top of the page
4.1 Therapeutic indications

Cisplatin is intended for the treatment of:

- Advance or metastasised testicular cancer

- Advance or metastasised ovarian cancer

- Advance or metastasised bladder carcinoma

- Advance or metastasised squamous cell carcinoma of the head and neck

- Advance or metastasised non-small cell lung carcinoma

- Advance or metastasised small cell lung carcinoma

Cisplatin is indicated in the treatment of cervical carcinoma in combination with other chemotherapeutics or with radiotherapy.

Cisplatin can be used as monotherapy and in combination therapy.

Go to top of the page
4.2 Posology and method of administration

Cisplatin 1 mg/ml Concentrate for solution for infusion is to be diluted before administration. For instructions for dilution of the product before administrate, see section 6.6.

The dilution should be administered only intravenously by infusion (see below). For administration, any device containing aluminium that may come in contact with cisplatin (sets for intravenous infusion, needles, catheters, syringes) must be avoided.


The cisplatin dosage depends on the primary disease, the expected reaction and on whether cisplatin is used for monotherapy or as a component of combination chemotherapy. The dosage directions are applicable for both adults and children.

For monotherapy, the following two dosage regimens are recommended:

- Single dose of 50 to 120 mg/m2 body surface every 3 to 4 weeks;

- 15 to 20 mg/m2/day for five days, every 3 to 4 weeks

If cisplatin is used in combination therapy, the dose of cisplatin must be reduced. A typical dose is 20mg/m2 or more once every 3 to 4 weeks.

For treatment of cervical cancer cisplatin is used in combination with radiotherapy. A typical dose is 40 mg/m2 weekly for 6 weeks.

For warning and precautions to be considered prior to the start of the next treatment cycle (see section 4.4).

In patients with renal dysfunction or bone marrow depression, the dose should be reduced adequately (see section 4.3).

The cisplatin solution for infusion prepared according to instructions (see section 6.6) should be administered by intravenous infusion over a period of 6 to 8 hours.

Adequate hydration must be maintained from 2 to 12 hours prior to administration until minimum 6 hours after the administration of cisplatin. Hydration is necessary to cause sufficient diuresis during and after treatment with cisplatin. It is realised by intravenous infusion of one of the following solutions:

- sodium chloride solution 0.9%;

- mixture of sodium chloride solution 0.9% and glucose solution 5% (1:1).

Hydration prior to treatment with cisplatin:

Intravenous infusion of 100 to 200ml/hour for a period of 6 to 12 hours, with a total amount of at least 1L.

Hydration after termination of the administration of cisplatin:

Intravenous infusion of another 2 litres at a rate of 100 to 200 ml per hour for a period of 6 to 12 hours.

Forced diuresis may be required should the urine secretion be less than 100 to 200 ml/hour after hydration. Forced diuresis may be realised by intravenously administering 37.5g mannitol as a 10% solution (375 ml mannitol solution 10%), or by administration of a diuretic if the kidney functions are normal.

The administration of mannitol or a diuretic is also required when the administrated cisplatin dose is higher than 60 mg/m2 of body surface.

It is necessary that the patient drinks large quantities of liquids for 24 hours after the cisplatin infusion to ensure adequate urine secretion.

Go to top of the page
4.3 Contraindications

Cisplatin may give allergic reactions in some patients. Use is contraindicated in those patients with a history of allergic reaction to cisplatin or other platinum containing compounds, or any component of the formulation.

Cisplatin induces nephrotoxicity which is cumulative. It is therefore contraindicated in patients with pre-existing renal impairment.

Cisplatin has also been shown to be cumulatively neurotoxic (in particular ototoxic) and should not be given to patients with pre-existing hearing impairment.

Cisplatin is also contraindicated in myelosuppressed patients and those who are dehydrated.

Patients receiving cisplatin should not breastfeed.

Concurrent administration of yellow fever vaccine is contraindicated.

Go to top of the page
4.4 Special warnings and precautions for use

This agent should only be administered under the direction of oncologists in specialist units under conditions permitting adequate monitoring and surveillance. Supportive equipment should be available to control anaphylactic reactions.

Cisplatin reacts with metallic aluminium to form a black precipitate of platinum. All aluminium containing I.V. sets, needles, catheters and syringes should be avoided.

The solution for infusion should not be mixed with other drugs or additives.

Appropriate monitoring and management of the treatment and its complications are only possible if adequate diagnosis and exact treatment conditions are available.

1. Nephrotoxicity

Cisplatin produces severe cumulative nephrotoxicity which may be potentiated by aminoglycoside antibiotics. Cisplatin should not be given more frequently than once every 3-4 weeks.

Repeat courses of cisplatin should not be given unless levels of serum creatinine are below 1.5 mg/100 ml (130 µmol/l) or blood urea below 55 mg/100 ml (9 mmol/l, and circulating blood levels are at an acceptable level. Since the renal toxicity of cisplatin is cumulative, measurement of BUN, serum creatinine or GFR should be performed prior to initiating therapy and prior to each subsequent course.

Adequate pre-treatment and 'during treatment' hydration should be ensured and such agents as mannitol given to minimise hazards of renal toxicity. A urine output of 100 ml/hour or greater will tend to minimise cisplatin nephrotoxicity. This can be accomplished by prehydration with 2 litres of an appropriate intravenous solution, and similar post cisplatin hydration (recommended 2,500 ml/m2/24 hours). If vigorous hydration is insufficient to maintain adequate urinary output, an osmotic diuretic may be administered (eg, mannitol).

The serum creatinine, BUN and creatinine clearance should be measured prior to initiating therapy and monitored throughout treatment with cisplatin.

2. Neuropathies

Severe cases of neuropathies have been reported.

These neuropathies may be irreversible and may manifest by paresthesia, areflexia and a proprioceptive loss and a loss of vibration perception. A loss of motor function has also been reported. A neurological examination must be carried out at regular intervals.

3. Ototoxicity

Ototoxicity has been observed in up to 31% of patients treated with a single dose of cisplatin 50 mg/m2, and is manifested by tinnitus and/or hearing loss in the high frequency range (4000 to 8000 Hz). Decreased ability to hear conversational tones may occur occasionally. Ototoxic effect may be more pronounced in children receiving cisplatin. Hearing loss can be unilateral or bilateral and tends to become more frequent and severe with repeated doses; however, deafness after initial dose of cisplatin has been reported rarely. Ototoxicity may be enhanced with prior simultaneous cranial irradiation and may be related to peak plasma concentration of cisplatin. It is unclear whether cisplatin induced ototoxicity is reversible. Careful monitoring by audiometry should be performed prior to initiation of therapy and prior to subsequent doses of cisplatin. Vestibular toxicity has also been reported. (See Undesirable Effects).

Since ototoxicity of cisplatin is cumulative, audiometric testing should be performed prior to initiating therapy and prior to each subsequent course of the drug (see section 4.8, Undesirable Effects).

4. Allergic phenomena

As with other platinum-based products, hypersensitivity reactions appearing in most cases during perfusion may occur, and necessitate discontinuation of the perfusion and an appropriate symptomatic treatment. Cross reactions, sometimes fatal, have been reported with all the platinum compounds (See Side Effects and Contraindications).

5. Hepatic function and haematological formula

The haematological formula and hepatic function must be monitored at regular intervals.

6. Carcinogenic potential

In humans, in rare cases the appearance of acute leukaemia has coincided with the use of cisplatin, which was in general associated with other leukaemogenic agent.

Cisplatin is a bacterial mutagen and causes chromosome aberrations in cultures on animal cells. Carcinogenicity is possible but has not been demonstrated. Cisplatin is teratogenic and embryo toxic in mice.

7. Injection site reactions

Injection site reactions may occur during the administration of cisplatin. Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during drug administration. A specific treatment for extravasation reactions is unknown at this time.


This cytostatic agent had a more marked toxicity than is usually found in antineoplastic chemotherapy.

Renal toxicity, which is above all cumulative, is severe and requires particular precautions during administration (see Side Effects and Administration).

Nausea and vomiting may be intense and require adequate antiemetic treatment.

Close supervision must also be carried out with regard to ototoxicity, myelodepression and anaphylactic reactions (see Side Effects).

Preparation of the intravenous solution


As with all other potentially toxic products, precautions are essential when handling the cisplatin solution. Skin lesions are possible in the event of accidental exposure to the product. It is advisable to wear gloves. In the event the cisplatin solution comes into contact with the skin or mucous membranes, wash the skin or mucous membranes vigorously with soap and water.

Conforming to the procedures appropriate for the manipulation and elimination of cytostatic agents is recommended.

Before administering the solution to the patient, verify the clarity of the solution and the absence of particles.

The vial stopper contains dry natural rubber (a derivative of latex), which may cause allergic reactions.

Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Cisplatin can be used in combination with other cytostatics with corresponding mechanisms of action. Additive toxicity might occur in such cases.

Myelosuppression induced by cisplatin will be additive to existent impairment or to the similar toxicity of other agents such as cephaloridine, frusemide, aminoglycosides, etc., administered concurrently.

Nephrotoxic substances:

Concomitant administration of nephrotoxic (e.g. cephalosporins, aminoglycosides, amphotericin B or contrast media) or ototoxic (e.g. aminoglycosides) medicinal products will potentiate the toxic effect of cisplatin on the kidneys. Nephrotoxicity might be exacerbated by aminoglycoside antibiotics, administered simultaneously or 1-2 weeks after treatment with cisplatin. The use of other potentially nephrotoxic drugs (e.g. amphotericine) is not recommended during treatment with cisplatin. During or after treatment with cisplatin caution is advised with predominantly renal eliminated substances, e.g. cytostatic agents such as bleomycin and methotrexate, because of potentially reduced renal elimination.

The renal toxicity of ifosfamide may be greater when used with cisplatin or in patients who have previously been given cisplatin.

Reduction of the blood's lithium values was noticed in a few cases after treatment with cisplatin combined with bleomycin and etoposide. It is therefore recommended to monitor the lithium values.

Ototoxic substances:

Concomitant administration of ototoxic (e.g. aminoglycosides, loop diuretics) medicinal products will potentiate the toxic effect of cisplatin on auditory function. Except for patients receiving doses of cisplatin exceeding 60 mg/m2, whose urine secretion is less than 1000 ml per 24 hours, no forced diuresis with loop diuretics should be applied in view of possible damage to the kidney tract and ototoxicity.

Ifosfamide may increase hearing loss due to cisplatin.

Weakened live vaccines:

Yellow fever vaccine is strictly contraindicated because of the risk of fatal systemic vaccinal disease (see section 4.3). In view of the risk of generalised illness, it is advisable to use an inactive vaccine if available.

Oral anticoagulants:

In the event of simultaneous use of oral anticoagulants, it is advisable to regularly check the INR.

Antihistamines, Phenothiazines and others:

Simultaneous use of antihistamines, buclizine, cyclizine, loxapine, meclozone, phenothiazines, thioxanthenes or trimethobenzamines may mask ototoxicity symptoms (such as dizziness and tinnitus).

Pyroxidine + altretamine combination:

During a randomised study of the treatment of advanced ovarian cancer, the response time was unfavourably affected when pyridoxine was used in combination with altretamine (hexamethylmelamine) and cisplatin.


Treatment with cisplatin prior to an infusion with paclitaxel may reduce the clearance of paclitaxel by 33% and therefore can intensify neurotoxicity.

Anticonvulsive substances/ Anti-epileptics:

Serum concentrations of anticonvulsive medicines may remain at subtherapeutic levels during treatment with cisplatin. For example; in patients receiving cisplatin and phenytoin, the serum level of phenytoin might be reduced. This is probably due to reduced absorption and/or increased metabolism. One should monitor the levels of phenytoin in plasma and adjust the dose accordingly.

Cisplatin may interact with aluminium (see section 4.2, Posology and method of administration).

4.6 Fertility, pregnancy and lactation

Use in Pregnancy:

Cisplatin may be toxic to the foetus when administered to a pregnant woman. The safe use of cisplatin in human pregnancy has not been established. Cisplatin has been shown to be mutagenic in bacteria. It produces chromosome aberrations in tissue-cultures of animal cells and is teratogenic and embryotoxic in mice. Cisplatin should not be used during pregnancy unless the clinician considers the risk to the individual patient to be justified.

During treatment with cisplatin and for a minimum of the following 6 months, appropriate measures must be taken to avoid pregnancy; this applies to patients of both sexes.

Genetic consultation is recommended if the patient wishes to have children after ending treatment.

Since a treatment with cisplatin may cause irreversible infertility, it is recommended that men, who wish to become fathers in the future, ask for advice regarding cryoconservation of their sperm prior to treatment.


Cisplatin is excreted in breast milk. Patients treated with cisplatin must not breastfeed.

Go to top of the page
4.7 Effects on ability to drive and use machines

No studies on the effects on ability to drive and use machines have been performed. Nevertheless, the profile of undesirable effects (like nephrotoxicity) may influence the ability to drive vehicles and use machinery.

Go to top of the page
4.8 Undesirable effects

The most frequently reported adverse events (>10%) of cisplatin were haematological (leukopenia, thrombocytopenia and anaemia), gastrointestinal (anorexia, nausea, vomiting and diarrhoea), ear disorders (hearing impairment), renal disorders (renal failure, nephrotoxicity, hyperuricaemia) and fever.

Serious toxic effects on the kidneys, bone marrow and ears have been reported in up to about one third of patients given a single dose of cisplatin; the effects are generally dose-related and cumulative. Ototoxicity may be more severe in children.

Frequencies are defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to ≤ 1/1,000); very rare (≤ 1/10,000), not known (cannot be estimated from the available data).

Table of Adverse Drug Events Reported During Clinical or Postmarketing Experience

(MedDRA terms)

System Organ Class


MedDRA term

Infections and infestations



Not known


Blood and lymphatic system disorders

Very common

Bone marrow failure, thrombocytopenia, leukopenia, anaemia

Not known

Coombs positive haemolytic anaemia, thrombotic microangiopathy (haemolytic uraemic syndrome), neutropenia

Neoplasms benign, malignant, and unspecified


Acute leukaemia

Immune system disorders


Anaphylactoidb reaction

Endocrine disorders

Not known

Blood amylase increased, inappropriate antidiuretic hormone secretion

Metabolism and nutrition disorders

Very common




Not known

Dehydration, hypokalaemia, hypophosphataemia, hyperuricaemia, hypocalcaemia, tetany

Nervous system disorders


Convulsion, neuropathy peripheral, leukoencephalopathy, reversible posterior leukoencephalopathy syndrome

Not known

Cerebrovascular accident, haemorrhagic stroke, ischaemic stroke, ageusia, cerebral arteritis, Lhermitte's sign, myelopathy, autonomic neuropathy

Eye disorders

Not known

Vision blurred, colour blindness acquired, blindness cortical, optic neuritis, papilloedema, retinal pigmentation

Ear and labyrinth disorders



Not known

Tinnitus, deafness

Cardiac disorders


Arrhythmia, bradycardia, tachycardia


Myocardial infarction

Very rare

Cardiac arrest

Not known

Cardiac disorder

Vascular disorders

Not known

Raynaud's phenomenon

Gastrointestinal disorders



Not known

Vomiting, nausea, anorexia, hiccups, diarrhoea

Hepatobiliary disorders

Not known

Hepatic enzymes increased, blood bilirubin increased

Respiratory, thoracic and mediastinal disorders

Not known

Pulmonary embolism

Skin and subcutaneous tissue disorders

Not known

Rash, alopecia

Musculoskeletal, connective tissue and bone disorders

Not known

Muscle spasms

Renal and urinary disorders

Not known

Renal failure acute, renal failurec , renal tubular disorder

Reproductive system and breast disorders


Abnormal spermatogenesis

General disorders and administration site condition

Not known

Pyrexia (very common), asthenia, malaise, injection site extravasationd

a: Infectious complications have lead to death in some patients.

b: Symptoms include facial edema (PT–face oedema), flushing, wheezing, bronchospasm, tachycardia, and hypotension will be included in the parentheses for anaphylactoid reaction in the AE frequency table.

c: Elevations in BUN and creatinine, serum uric acid, and/or decrease in creatinine clearance are subsumed under renal insufficiency/failure.

d: Local soft tissue toxicity including cellulitis, fibrosis, and necrosis (common) pain (common), oedema (common) and erythema (common) as the result of extravasation.

Nephrotoxicity: Renal toxicity has been shown in 28-38% of patients treated with a single dose of cisplatin 50 mg/m2 . Renal toxicity becomes more prolonged and severe with repeated courses of the drug.

Gastrointestinal toxicity: Nausea and vomiting occur in the majority of patients, usually starting within 1 hour of treatment and lasting up to 24 hours. Anorexia, nausea and occasional vomiting may persist for up to a week.

Ocular Toxicity: There have been reports of optic neuritis, papilloedema and cerebral blindness following treatment with cisplatin. Improvement and/or total recovery usually occurs following immediate discontinuation. Blurred vision and altered colour perception have been reported after the use of regimens with higher doses of cisplatin or greater dose frequencies than those recommended.

Ototoxicity: Ototoxicity has occurred in up to 31% of patients treated with a single dose of cisplatin 50 mg/m2. Ototoxicity may be more severe in children and more frequent and severe with repeated doses. Careful monitoring should be performed prior to initiation of therapy and prior to subsequent doses of cisplatin.

Unilateral or bilateral tinnitus, which is usually reversible, and/or hearing loss in the high frequency range may occur.

The overall incidence of audiogram abnormalities is 24%, but large variations exist. These abnormalities usually appear within 4 days after drug administration and consist of at least a 15 decibel loss in pure tone threshold. The damage seems to be cumulative and is not reversible. The audiogram abnormalities are most common in the 4000-8000 Hz frequencies.

Haemotoxicity: Myelosuppression is observed in about 30% of patients treated with cisplatin. Leucopenia and thrombocytopenia are more pronounced at higher doses. The nadirs in circulating platelets and leucocytes generally occur between days 18-23 (range 7.3 to 45) with most patients recovering by day 39 (range 13 to 62). Leucopenia and thrombocytopenia are more pronounced at doses greater than 50 mg/m2. Anaemia (decreases of greater than 2 g% haemoglobin) occurs at approximately the same frequency, but generally with a later onset than leucopenia and thrombocytopenia. Subsequent courses of cisplatin should not be instituted until platelets are present at levels greater than 100,000/mm3 and white cells greater than 4,000/mm3. A high incidence of severe anaemia requiring transfusion of packed red cells has been observed in patients receiving combination chemotherapy including cisplatin.

Anaphylaxis: Reactions possibly secondary to cisplatin therapy have been occasionally reported in patients who were previously exposed to cisplatin. Patients who are particularly at risk are those with a prior history or family history of atopy. Facial oedema, wheezing, tachycardia, hypotension and skin rashes of urticarial non-specific maculopapular type can occur within a few minutes of administration. Serious reactions seem to be controlled by I.V. adrenaline, corticosteroids or antihistamines.

Neurotoxicity: Neurotoxicity may occur. It is cumulative and may be irreversible. It is generally characterised by neuropathies, but seizures and taste loss have occurred.

Peripheral neuorpathies with paresthesia in both upper and lower extremities, tremor and loss of taste have been observed in some patients, generally those treated with repeated courses.

Hypomagnesaemia and Hypocalcaemia: Hypomagnesaemia occurs quite frequently with cisplatin administration, while hypocalcaemia occurs less frequently. The loss of magnesium seems to be associated with renal tubular damage which prevents resorption of this cation. Where both electrolytes are deficient, tetany may result. It does not appear to be dose related. Monitoring of electrolytes is necessary.

Electrolyte Disturbances: Hyponatraemia, hypokalaemia and hypophosphataemia can occur.

Hyperuricaemia: Hyperuricaemia occurring with cisplatin is more pronounced with doses greater than 50 mg/m2. Allopurinol effectively reduces uric acid levels.

Cardiac and Vascular Disorders: Cardiac reactions including tachycardia and arrhythmia have been reported. Vascular toxicities coincident with the use of cisplatin in combination with other antineoplastic agents have been reported rarely. These events may include myocardial infarction, cerebrovascular accident, thrombotic microangiopathy (Haemolytic uraemic syndrome) or cerebral arteritis.

Other Toxicities: There are also reports of Raynaud's phenomenon occurring in patients treated with the combination of bleomycin, vinblastine and with or without cisplatin. It has been suggested that hypomagnesaemia developing with the use of cisplatin may be an added, although not essential factor, associated with this event. However the cause of this Raynaud's phenomenon is currently unknown.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in HPRA Pharmacovigilance, Earlsfort Terrace , IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, e-mail: medsafety@hpra.ie

Go to top of the page
4.9 Overdose


Overdosage can be expected to cause the toxic effects described above, but to an exaggerated degree. Adequate hydration and osmotic diuresis may help reduce the toxicity of cisplatin if administered promptly following overdosage. Convulsions may be treated with appropriate anticonvulsants.

An acute overdose of cisplatin may result in renal failure, liver failure, deafness, ocular toxicity (including detachment of the retina), significant myelosuppression, untreatable nausea and vomiting and/or neuritis. Renal function, cardiovascular function and blood counts should be monitored daily in order to assess the potential toxicity to these systems. Serum magnesium and calcium levels should be carefully monitored as should symptoms and signs of voluntary muscle irritability. If symptomatic tetany develops, electrolyte supplements should be administered. Serum liver enzymes and uric acid should also be monitored daily after an acute overdose. An overdose may be fatal.

There is no specific antidote in the event of an overdosage of cisplatin. Even if haemodialysis is initiated 4 hours after the overdose it has little effect on the elimination of cisplatin from the body following a strong and rapid fixation of cisplatin to proteins.

Treatment in the event of an overdose consists of general support measures.

If fever develops during prolonged myelosuppression, appropriate presumptive antibiotic coverage should be instilled after cultures have been obtained.

Go to top of the page

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other Antineoplastic Agents

ATC code: L01XA01

Cisplatin has biochemical properties similar to those of bifunctional alkylating agents. The drug inhibits DNA synthesis by producing intrastrand and interstrand cross links in DNA. Protein and RNA synthesis are also inhibited to a lesser extent.

Although the principal mechanism of action of cisplatin appears to be inhibition of DNA synthesis, other mechanisms, including enhancement of tumour immunogenicity, may be involved in its antineoplastic activity. Cisplatin also has immunosuppressive, radiosensitising, and antimicrobial properties.

Cisplatin does not appear to be cell cycle specific.

Go to top of the page
5.2 Pharmacokinetic properties

There is good uptake of cisplatin by the kidneys, liver and intestine. More than 90% of platinum containing species remaining in the blood are bound (possibly irreversibly) to plasma proteins. Penetration into the CSF is poor although significant amounts of cisplatin can be detected in intracerebral tumours.

The clearance of total platinum from plasma is rapid during the first four hours after intravenous administration, but then proceeds more slowly because of covalent binding to serum proteins. Levels of unbound platinum fall with a half-life of 20 minutes to 1 hour depending on the rate of drug infusion.

The elimination of intact drug and various platinum-containing biotransformation products is via the urine. About 15-25% of administered platinum is rapidly excreted in the first 2-4 hours after administration of cisplatin. This early excretion is mostly of intact cisplatin. In the first 24 hours after administration, 20-80% is excreted; the remainder representing drug bound to tissues or plasma protein.

Go to top of the page
5.3 Preclinical safety data

Cisplatin has been shown to be mutagenic. It may also have an anti-fertility effect. Other anti-neoplastic substances have been shown to be carcinogenic and this possibility should be borne in mind in long term use of cisplatin.

Go to top of the page

Go to top of the page
6.1 List of excipient(s)

Mannitol (E421)

Sodium chloride

Dilute hydrochloric acid (for pH adjustment)

Water for injections

Go to top of the page
6.2 Incompatibilities

There is a total loss of cisplatin in 30 minutes at room temperature when mixed with metoclopramide and sodium metabisulphite in concentrations equivalent to those that would be found on mixing with a commercial formulation of metoclopramide.

Cisplatin and sodium bisulphite have been known to react chemically. Such antioxidants might inactivate cisplatin before administration if they are present in intravenous fluids.

Interaction with aluminium:

Cisplatin may interact with metal aluminium to form a black precipitate of platinum. All aluminium-containing IV sets, needles, catheters and syringes should be avoided.

Go to top of the page
6.3 Shelf life

Prior to first use: 24 months

In use: In use: See section 6.4, Special precautions for storage.

Go to top of the page
6.4 Special precautions for storage

Prior to first use: Do not store above 25°C. Do not refrigerate or freeze. Keep vial in the outer carton in order to protect from light.

In use: Following dilution in 0.9% Sodium Chloride Injection to a final concentration of 0.15 mg/ml, chemical and physical in-use stability has been demonstrated for up to 14 days at 4°C when protected from light. From a microbiological point of view, however, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8°C unless dilution has taken place in controlled and validated aseptic conditions.

Go to top of the page
6.5 Nature and contents of container

10 mg/10 ml, 50 mg/50 ml and 100 mg/100 ml presentations in Type I amber glass vials and Onco-Tain vials. Packs contain a single vial.

Go to top of the page
6.6 Special precautions for disposal and other handling

Single use only. Discard any unused contents.

Refer to local cytotoxic handling guidelines.


Cisplatin 1 mg/ml Sterile Concentrate should be added to 2 litres of 0.9% sodium chloride injection.


Should be administered only by or under the direct supervision of a qualified physician who is experienced in the use of cancer chemotherapeutic agents.

Preparation (Guidelines):

1. Chemotherapeutic agents should be prepared for administration only by professionals who have been trained in the safe use of the preparation.

2. Operations such as reconstitution, dilution and transfer to syringes should be carried out only in the designated area.

3. The personnel carrying out these procedures should be adequately protected with clothing, gloves and eye shield.

4. Pregnant personnel are advised not to handle chemotherapeutic agents


(a) In the event of contact with the skin or eyes, the affected area should be washed with copious amounts of water or normal saline. A bland cream may be used to treat the transient stinging of skin. Medical advice should be sought if the eyes are affected.

(b) In the event of spillage, operators should put on gloves and mop up the spilled material with a sponge kept in the area for that purpose. Rinse the area twice with water. Put all solutions and sponges into a plastic bag and seal it.


Syringes, container, absorbent materials, solution and any other contaminated material should be placed in a thick plastic bag or other impervious container and incinerated.

Go to top of the page

Hospira UK Limited


Honey Lane




United Kingdom

Go to top of the page

PA 437/4/7

Go to top of the page

Date of first authorisation: 19th November 1986

Date of last renewal: 18th December 2006

Go to top of the page

July 2017

Ref: gxCP 1_0

Link to this document from your website:

Document Links

  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Active Ingredients